Kazushige Moriyama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kazushige Moriyama has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Akihiro Matsumoto
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
1 shared publication - Eiji Tanaka
Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan
1 shared publication - Hiroshi Yatsuhashi
Clinical Research Center, National Hospital Organization (NHO) Nagasaki Medical Center, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
1 shared publication - Katsumi Aoyagi
New Product Development Department, Fujirebio Inc., Hachioji, Tokyo, Japan
1 shared publication - Masayasu Imaizumi
New Product Development Department, Fujirebio Inc., Hachioji, Tokyo, Japan
1 shared publication - Shuhei Nishiguchi
Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan
1 shared publication
Latest Publications
- 26 July 2016
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 52 (3) , 376-384
Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody
Background Hepatitis B surface antigen (HBsAg) is used as a clinical marker of hepatitis B virus (HBV) infection. However, conventional HBsAg assays have so far failed to accurately detect HBsAg in blood because of interference by patient-derived antibodies against HBsAg (HBsAb). Methods We developed a novel, fully automated assay system that can detect total HBsAg in blood, including antigens complexed with HBsAb. The immunoassay inactivates HBsAb via a simple pretreatment step to dissociate the HBsAg molecule from HBsAg–HBsAb complexes and thereby estimate total HBsAg. Accordingly, the test has been termed the “immunoassay for total antigen including complex via pretreatment (iTACT)-HBsAg.” Results The recovery rate of HBsAg in the presence of HBsAb was greater than 87 % at a cutoff value set at 5.0 mIU/mL on the basis of data from 545 healthy controls. Analyses using serial serum samples from 25 HBV carriers who became negative for HBsAg during follow-up showed that the iTACT-HBsAg could detect HBsAg over a period of years despite a loss in detection by conventional assays and was able to detect HBsAg in 39 (53 %) of 73 samples with HBsAb. Conclusions The new iTACT-HBsAg assay appears to detect total HBsAg with high sensitivity, even in the presence of HBsAb, and may useful in identifying subclinical or occult HBV carriers.
- 26 July 2016
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 52 (3) , 376-384
Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody
Background Hepatitis B surface antigen (HBsAg) is used as a clinical marker of hepatitis B virus (HBV) infection. However, conventional HBsAg assays have so far failed to accurately detect HBsAg in blood because of interference by patient-derived antibodies against HBsAg (HBsAb). Methods We developed a novel, fully automated assay system that can detect total HBsAg in blood, including antigens complexed with HBsAb. The immunoassay inactivates HBsAb via a simple pretreatment step to dissociate the HBsAg molecule from HBsAg–HBsAb complexes and thereby estimate total HBsAg. Accordingly, the test has been termed the “immunoassay for total antigen including complex via pretreatment (iTACT)-HBsAg.” Results The recovery rate of HBsAg in the presence of HBsAb was greater than 87 % at a cutoff value set at 5.0 mIU/mL on the basis of data from 545 healthy controls. Analyses using serial serum samples from 25 HBV carriers who became negative for HBsAg during follow-up showed that the iTACT-HBsAg could detect HBsAg over a period of years despite a loss in detection by conventional assays and was able to detect HBsAg in 39 (53 %) of 73 samples with HBsAb. Conclusions The new iTACT-HBsAg assay appears to detect total HBsAg with high sensitivity, even in the presence of HBsAb, and may useful in identifying subclinical or occult HBV carriers.